Phlebopathies: from pathogenesis to treatment

Introduction. The prevalence of phlebopathies varies from 15 to 31%. The QoL of patients with phlebopathies is impaired. Phlebotropic therapy is the main method for treating phlebopathies.
Aim. Evaluation of the efficacy and safety of micronized purified flavonoid fraction (MPFF) (Troxaktiv).
Materials and methods. A total of 129 females aged 18 to 45 years (average age of 35,2 ± 4,1 years) were included in the open observational study. To exclude pathology of the principal veins of the lower extremities, all patients underwent ultrasound examination, as well as photoplethysmography with automatic measurements of the venous refilling time and the power of the calf muscle-venous pump. All patients were divided into three groups: Group 1 received MPFF at a daily dose of 1000 mg only, Group 2 – class I compression hosiery in addition to MPFF, Group 3 – a course of psychotherapy and guidelines on lifestyle changes, augmentation of physical activity, etc.
Results. Due to ongoing treatment measures, positive changes with decreased number of complaints and their intensity were observed. Positive changes occurred mainly in the groups of patients receiving phlebotropic therapy and combined phlebotropic/compression therapy: the number of patients with vein-specific symptoms decreased by more than half, while 31 patients reported the persistence in complaints at baseline level or their slight decrease while taking psychotherapy course and lifestyle changes. The specific therapy groups reported a significant dynamic reduction in the feeling of heaviness and pain as well as night cramps in the calves.
Discussion. In the presented study, the patients were prescribed MPFF/Troxaktiv™ at a daily dose of 1000 mg, both as monotherapy and in combination with compression. A significant decrease in the frequency and severity of vein-specific symptoms and a significant increase in the patients’ quality of life was recorded in both of these groups. Photoplethysmography results showed an improvement in elastic rebound properties of the venous wall. All patients were satisfied with the treatment.
Conclusion. MPFF/Troxaktiv™ has demonstrated high efficacy and safety in the treatment of patients with phlebopathies of various origins.

1. Rabe E, Guex J-J, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. Available at: https://pubmed.ncbi.nlm.nih.gov/22466974.

2. Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global epidemiology of chronic venous disease: a systematic review with pooled prevalence analysis. Ann Surg. 2021;274(6):971–976. https://doi.org/10.1097/SLA.0000000000004631.

3. Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020;8(3):342–352. https://doi.org/10.1016/j.jvsv.2019.12.075.

4. Eklof B, Perrin M, Delis KT, Rutherford RB, Gloviczki P. Updated terminology of chronic venous disorders: the VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg. 2009;49(2):498–501. https://doi.org/10.1016/j.jvs.2008.09.014.

5. Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. Available at: https://pubmed.ncbi.nlm.nih.gov/22466974.

6. Guex JJ, Rabe E, Escotto SI, Escudero J-R, Scuderi A, Yuwono HS. The ‘‘C0s’’ patient: worldwide results from the Vein Consult Program. Phlebolymphology. 2012;19:182–192. Available at: https://www.phlebolymphology.org/the-c0s-patient-worldwide-results-from-thevein-consult-program.

7. Andreozzi G, Signorelli S, Di Pino L, Garozzo S, Cacciaguerra G, Leone A, Martini R. Varicose symptoms without varicose veins: the hypotonic phlebopathy, epidemiology and pathophysiology. The Acireale project. Minerva Cardioangiol. 2000;48(10):277–285. Available at: https://pubmed.ncbi.nlm.nih.gov/11195857.

8. Serra R, Grande R, Butrico L, Fugetto F, De Franciscis S. Epidemiology, diagnosis and treatment of chronic venous disease: a systematic review. Chirurgia. 2016;29(2):34–45. Available at: https://www.minervamedica.it/en/journals/chirurgia/article.php?cod=R20Y2016N02A0034#.

9. Serra R, Andreucci M, De Caridi G, Massara M, Mastroroberto P, de Franciscis S. Functional chronic venous disease: A systematic review. Phlebology. 2017;32(9):588–592. https://doi.org/10.1177/0268355516686451.

10. Nicolaides AN. Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. Angiology. 2005;56(Suppl. 1):11–19. https://doi.org/10.1177/00033197050560i103.

11. Vital A, Carles D, Serise JM, Boisseau MR. Evidence for unmyelinated C fibres and inflammatory cells in human varicose saphenous vein. Int J Angiol. 2010;19(2):e73–77. https://doi.org/10.1055/s-0031-1278374.

12. Serra R, Gallelli L, Perri P, De Francesco EM, Rigiracciolo DC, Mastroroberto P et al. Estrogen Receptors and Chronic Venous Disease. Eur J Vasc Endovasc Surg. 2016;52(1):114–118. https://doi.org/10.1016/j.ejvs.2016.04.020.

13. Chiesa R, Marone EM, Limoni C, Volontè M, Petrini O. Chronic venous disorders: correlation between visible signs, symptoms, and presence of functional disease. J Vasc Surg. 2007;46(2):322–330. https://doi.org/10.1016/j.jvs.2007.04.030.

14. Bogachev VYu. Hormone-induced phlebopathy. A new problem of modern phlebology. Angiology and Vascular Surgery. 2002;(3):50–54. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2002/3/7.htm.

15. Tsoukanov YuT, Tsoukanov AYu. Clinical assessment of phlebopathy severity by specification ofleg heaviness symptom. Angiology and Vascular Surgery. 2003;(1):67–70. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2003/1/8.htm.

16. Tsukanov YuT, Tsukanov AYu, Bazhenov VN. The effect of oral contraceptives on the orthostatic diameter of lower limb major veins and its correction. Angiology and Vascular Surgery. 2008;(1):75–77. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2008/1/10.htm.

17. Tsukanov YuT, Tsukanov AYu, Bazhenov VN, Kornienko IF, Vasilevich VV. Drug-mediated correction of negative phlebotropic effects of hormone replacement therapy in women. Angiology and Vascular Surgery. 2009;(3):87–91. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2009/3/13.htm.

18. Del Turco S, Vianello A, Ragusa R, Caselli C, Basta G. COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge? Thromb Res. 2020;196:143–151. https://doi.org/10.1016/j.thromres.2020.08.039.

19. Nägele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020;314:58–62. https://doi.org/10.1016/j.atherosclerosis.2020.10.014.

20. Anaya JM, Rojas M, Salinas ML, Rodríguez Y, Roa G, Lozano M et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun Rev. 2021;20(11):102947. https://doi.org/10.1016/j.autrev.2021.102947.

21. Bogachev VYu, Boldin BV, Turkin PYu, Dzhenina OV. COVID-19-associated phlebopathy as a current problem of modern phlebology. Ambulatornaya Khirurgiya. 2022;19(2):13–20. (In Russ.) https://doi.org/10.21518/1995-1477-2022-19-2.

22. Mansilha A, Sousa J. Pathophysiological mechanisms of chronic venous disease and implications for venoactive drug therapy. Int J Mol Sci. 2018;19(6):1669. https://doi.org/10.3390/ijms19061669.

23. Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg. 2011;41(1):117–125. https://doi.org/10.1016/j.ejvs.2010.09.025.

24. Rabe E, Agus G, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015;34(5):428–436. Available at: https://pubmed.ncbi.nlm.nih.gov/25972136.

25. Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebocontrolled trials. Int Angiol. 2018;37(2):143–154. https://doi.org/10.23736/S0392-9590.18.03975-5.

26. Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018;37(3):181–254. https://doi.org/10.23736/S0392-9590.18.03999-8.

27. Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B et al. Management of Chronic Venous Disorders of the Lower Limbs. Guidelines According to Scientific Evidence. Part II. Int Angiol. 2020;39(3):175–240. https://doi.org/10.23736/S0392-9590.20.04388-6.

28. Mazayshvili KV, Kian RA, Khlevtova TV, Tsypliashuk AV, Suhanov AV, Angelova VA, Semkin VD. The Patient with C0S and C1S: Should a Phlebopathy Be Considered? Phlebology. 2016;(3):137–140. (In Russ.) https://doi.org/10.17116/flebo2016103137-140.

29. Van der Velden SK, Shadid NH, Nelemans PJ, Sommer A. How specific are venous symptoms for diagnosis of chronic venous disease? Phlebology. 2014;29(9):580–586. https://doi.org/10.1177/0268355513515859.

30. Wrona M, Jöckel KH, Pannier F, Bock E, Hoffmann B, Rabe E. Association of Venous Disorders with Leg Symptoms: Results from the Bonn Vein Study 1. Eur J Vasc Endovasc Surg. 2015;50(3):360–367. https://doi.org/10.1016/j.ejvs.2015.05.013.

31. Balakhonova TV, Ershova AI, Ezhov MV, Barbarash OL, Bershtein LL, Bogachev VYu et al. Focused vascular ultrasound. Consensus of Russian experts. Cardiovascular Therapy and Prevention (Russian Federation). 2022;21(7):3333.(In Russ.) https://doi.org/10.15829/1728-8800-2022-3333.

32. Shaydakov EV, Sannikov AB. Photoplethysmographic characteristics of the efficiency of the calf muscle-venous pump in norm and in patients with cvd of various clinical classes according to CEAP. Ambulatornaya Khirurgiya. 2021;18(1):103–119. (In Russ.) https://doi.org/10.21518/1995-1477-2021-18-1-103-119.

33. Launois R, Mansilha A, Jantet G. International psychometric validation of the Chronic Venous Disease quality of life Questionnaire (CIVIQ-20). Eur J Vasc Endovasc Surg. 2010;40(6):783–789. https://doi.org/10.1016/j.ejvs.2010.03.034.

34. Kuet ML, Lane TR, Anwar MA, Davies AH. Comparison of disease-specific quality of life tools in patients with chronic venous disease. Phlebology. 2014;29(10):648–653. https://doi.org/10.1177/0268355513501302.

35. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and nonrandomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384. https://doi.org/10.1136/jech.52.6.377.

36. Blazek C, Amsler F, Blaettler W, Keo HH, Baumgartner I, Willenberg T. Compression hosiery for occupational leg symptoms and leg volume: a randomized crossover trial in a cohort of hairdressers. Phlebology. 2013;28(5):239–247. https://doi.org/10.1258/phleb.2011.011108.

37. Jantet G. RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids. Angiology. 2000;51(1):31–37. https://doi.org/10.1177/000331970005100107.

38. Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology. 2002;53(3):245–256. https://doi.org/10.1177/000331970205300301.

39. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016;4(4):CD003229. https://doi.org/10.1002/14651858.CD003229.pub3.

40. Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020;11(11):CD003229. https://doi.org/10.1002/14651858.CD003229.pub4.

41. Tsukanov Y, Nicolaichuk A. Changes in clinical manifestations and biophysical properties of the great saphenous vein in transient premenstrual phlebopathy after 12 months’ treatment with micronized purified flavonoid fraction. Phlebolymphology. 2020;27(1):36–42. Available at: https://www.phlebolymphology.org/changes-in-clinical-manifestations-and-biophysical-properties-of-the-greatsaphenous-vein-in-transient-premenstrual-phlebopathy-after-12-months-treatment-with-micronized-purified-flavonoid-f/.

42. De Maeseneer MG, Kakkos SK, Aherne T, Baekgaard N, Black S, Blomgren L et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. https://doi.org/10.1016/j.ejvs.2021.12.024.